Pfizer presented clinical data for Ecnoglutide, a cAMP-biased GLP-1 receptor agonist, at the 2026 American Diabetes Association (ADA) conference. The head-to-head study demonstrated that Ecnoglutide 2.4mg achieved 12.8% average weight loss at 20 weeks compared to 9.5% for semaglutide 2.4mg, representing approximately 35% greater efficacy. The data release follows Pfizer's March 2026 approval of Ecnoglutide for weight management in China and the company's acquisition of Metsera for over $9 billion to expand its obesity treatment pipeline. Prof. Ji Linong of Peking University People's Hospital stated the study provides the first direct clinical evidence validating the cAMP-biased GLP-1 receptor agonist mechanism's clinical advantages. The results position Pfizer as a significant entrant in the global weight-loss drug market currently dominated by semaglutide, which generated $36.1 billion in sales in 2025.
Ecnoglutide Demonstrates Superior Weight Loss in Head-to-Head Trial Against Semaglutide
The head-to-head study presented at the 2026 ADA conference compared Ecnoglutide 2.4mg directly against semaglutide 2.4mg over 20 weeks. Subjects receiving Ecnoglutide achieved 12.8% average weight reduction from baseline, while the semaglutide group achieved 9.5% reduction. In deep weight-loss metrics, Ecnoglutide's rate of subjects achieving ≥10% weight loss was nearly double that of semaglutide. For the baseline threshold of ≥5% weight loss, Ecnoglutide achieved a 98.8% attainment rate compared to semaglutide's 88.4%.
Waist circumference decreased by an average of 10.5cm in the Ecnoglutide group versus 8.7cm in the semaglutide group at 20 weeks, representing a 20% greater reduction. Ecnoglutide also showed significant improvements in neck circumference, arm circumference, and overall body fat distribution.
Adverse event rates at 20 weeks were lower for Ecnoglutide 2.4mg compared to semaglutide 2.4mg: nausea occurred in 13.4% versus 21.0%, vomiting in 11.0% versus 12.3%, and abdominal bloating in 4.9% versus 9.9%.
Prof. Ji Linong stated: "This study is the first to verify with direct clinical evidence the clinical advantages of the cAMP-biased GLP-1 receptor agonist innovative mechanism. By optimizing GLP-1 receptor signal transduction, it can achieve clinical benefits superior to traditional GLP-1 receptor agonists, providing high-quality evidence-based medical evidence for the weight management field."
Prof. Ji noted that central obesity (abdominal fat accumulation) is a core risk factor for type 2 diabetes, metabolic syndrome, and cardiovascular disease. "Ecnoglutide significantly reduces body weight while effectively improving central obesity and localized fat accumulation, improving body shape while reducing related metabolic disease risk," he stated.
cAMP-Biased Mechanism Reduces Adverse Events While Maintaining Efficacy
Ecnoglutide is the world's first cAMP-biased GLP-1 receptor agonist. The mechanism selectively activates the cAMP signaling pathway while reducing β-arrestin recruitment, decreasing receptor desensitization and internalization. This design translates the 2012 Nobel Prize in Chemistry discovery (G protein-coupled receptor function) into clinical application.
Traditional GLP-1 drugs activate both effective metabolic pathways and pathways that trigger gastrointestinal adverse effects simultaneously. The cAMP-biased mechanism activates beneficial weight-loss pathways while minimizing activation of pathways associated with nausea and vomiting.
SLIMMER Trial Shows 15.4% Weight Loss in Chinese Population
The SLIMMER study, which supported Ecnoglutide's approval in China, is the largest phase III clinical trial in a Chinese weight-loss population to date. At 48 weeks of treatment, subjects achieved an average weight reduction of 15.4%, with 92.8% of subjects achieving weight loss of 5% or more.
Waist circumference decreased by an average of 12.8cm. Subjects with fatty liver at baseline experienced an average 53.1% reduction in liver fat content. Uric acid levels decreased by an average of 54.3 μmol/L.
Gastrointestinal adverse reactions were mostly transient, with a discontinuation rate due to gastrointestinal adverse events of only 0.6%.
Pfizer Expands Weight-Loss Portfolio Through Metsera Acquisition and Yaopharma Partnership
Pfizer acquired next-generation weight-loss drug developer Metsera for over $9 billion, significantly expanding its global weight-loss product portfolio. The company has constructed a pipeline covering daily oral, weekly, and monthly injection administration routes.
In late 2025, Pfizer China reached a licensing agreement with Sinopharm subsidiary Yaopharma for an oral GLP-1 weight-loss drug, with a maximum total value of nearly $2 billion. In early 2026, Pfizer obtained exclusive commercialization rights for Ecnoglutide in mainland China. Ecnoglutide received approval for weight management indication in China in March 2026.
FAQ
What weight loss did Ecnoglutide achieve compared to semaglutide in the 2026 ADA study?
Ecnoglutide 2.4mg achieved 12.8% average weight loss at 20 weeks compared to 9.5% for semaglutide 2.4mg in the head-to-head study presented at the 2026 ADA conference. This represents approximately 35% greater efficacy. Ecnoglutide also achieved a 98.8% rate of subjects reaching ≥5% weight loss versus 88.4% for semaglutide.
How does Ecnoglutide's cAMP-biased mechanism differ from traditional GLP-1 drugs?
Ecnoglutide selectively activates the cAMP signaling pathway while reducing β-arrestin recruitment, decreasing receptor desensitization and internalization. Traditional GLP-1 drugs activate both beneficial metabolic pathways and pathways that trigger gastrointestinal side effects simultaneously. The cAMP-biased design resulted in lower adverse event rates: nausea occurred in 13.4% of Ecnoglutide subjects versus 21.0% for semaglutide at 20 weeks.
What strategic moves has Pfizer made in the weight-loss drug market?
Pfizer acquired Metsera for over $9 billion to expand its obesity treatment pipeline. In late 2025, Pfizer reached a licensing agreement with Yaopharma for an oral GLP-1 drug worth up to nearly $2 billion. Pfizer obtained exclusive commercialization rights for Ecnoglutide in mainland China in early 2026, and the drug received approval for weight management in China in March 2026.
